{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:56:36Z","timestamp":1722952596553},"reference-count":30,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ijantimicag.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T21:31:16Z","timestamp":1377293476000},"page":"390-394","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients"],"prefix":"10.1016","volume":"42","author":[{"given":"Jiun-Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Hsun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2013.07.010_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(08)70002-5","article-title":"Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus","volume":"31","author":"Gould","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0010","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/infdis\/jir275","article-title":"Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?","volume":"204","author":"Holland","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.01133-10","article-title":"Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"55","author":"van Hal","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0035","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0040","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.00422-06","article-title":"Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"50","author":"Howden","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0050","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","article-title":"Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore","volume":"28","author":"Fong","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0055","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jac\/dkr169","article-title":"Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"66","author":"Khatib","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2334-11-335","article-title":"The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia","volume":"11","author":"Honda","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/596629","article-title":"Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia","volume":"199","author":"Maor","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0070","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.02135-08","article-title":"Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years","volume":"47","author":"Musta","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0075","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1128\/AAC.00757-12","article-title":"Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia","volume":"56","author":"Han","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/jac\/dks131","article-title":"Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus","volume":"67","author":"Park","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0085","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/JCM.00265-08","article-title":"Evaluation of a new Etest vancomycin\u2013teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA","volume":"46","author":"Yusof","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1128\/JCM.38.3.1008-1015.2000","article-title":"Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus","volume":"38","author":"Enright","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0110","doi-asserted-by":"crossref","first-page":"e21217","DOI":"10.1371\/journal.pone.0021217","article-title":"Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections","volume":"6","author":"van Hal","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0115","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1086\/596511","article-title":"Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection","volume":"199","author":"Peleg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/649572","article-title":"Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?","volume":"201","author":"Lalueza","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2180-8-39","article-title":"Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"8","author":"Howden","year":"2008","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0130","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/606027","article-title":"Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance","volume":"200","author":"Bae","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0135","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0145","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/AAC.00206-09","article-title":"Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China","volume":"53","author":"Sun","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.07.010_bib0150","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/jac\/dks128","article-title":"Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients","volume":"67","author":"Rojas","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T13:14:24Z","timestamp":1596374064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913002690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0924857913002690"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.07.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}